Scynexis Inc. took a significant step toward the approval of the first new class of antifungal agents since the 1980s with the successful Phase III VANISH-303 trial results in vulvovaginal candidiasis, commonly known as a yeast infection, for its ibrexafungerp (SCY-078) 7 November and now awaits data from a second pivotal study, expected next year, to file for US approval in acute VVC.
Ibrexafungerp is a first-in-class glucan synthase inhibitor being developed as both an oral and intravenous therapy for fungal infections caused...








